About Us
Our Company
Management & Board
Who We Help
Our Approach
Toll-Like Receptor Activation
Publications & Presentations
Areas of Focus
Immuno-Oncology
Pipeline & Programs
Investor Relations
Join Us
×
Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase 1/2 study in patients with anti-PD-1 refractory metastatic melanoma